Sector News

Sandoz opens new UK HQ

January 6, 2020
Life sciences

Novartis’ Sandoz division has announced a new UK headquarters based in Camberley, Surrey.

The global leader in generics and biosimilars announced that it has opened the new building at Watchmoor Park, forming part of the company’s “Transforming Sandoz” strategy, which aims to enable the business to “strengthen its role as a leading provider of medicines to the NHS.”

The company says that the site will be the centre of its UK operations, which encompasses a range of operational functions. It also announced that it is “are hugely excited” to be opening the “new home”, and that “The move is part of our mission to build a long-term future in the UK and to continue working with the NHS to ensure access to generic medicines and biosimilars” said Timothy de Gavre, Sandoz UK country head.

He continued, “Watchmoor Park is the right home for us and our customers; offering convenience, an ideal location and appropriate facilities for our business requirements. As a company, we are on an exciting journey and we look forward to supporting the progress of Watchmoor Park as a thriving

By Anna Smith

Source: PharmaTimes

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.